Amgen Inc AMGN
News
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Amgen Down Over 13%, Worst Performer in the DJIA and Nasdaq 100 So Far Today — Data Talk
Amgen's obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come